



gritstone

ONCOLOGY

Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference

February 20, 2019

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- [Gritstone Oncology](#) (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Marc Bellemin, M.B.A., executive vice president and chief financial officer, and Karin Jooss, Ph.D., executive vice president of research and chief scientific officer, will present a company overview on Wednesday, February 27, 2019 at 10:30 a.m. EST during the 8th Annual SVB Leerink Global Healthcare Conference in New York.

A live audio webcast will be available within the Investors & Media section of the Gritstone Oncology website at <https://ir.gritstoneoncology.com/investors/events>. An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy beginning Phase 1 clinical testing. Gritstone's second product candidate, SLATE-001, is a shared neoantigen ("off-the-shelf") immunotherapy which is advancing towards the clinic. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts

Media:

Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:

Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhousesa.com



Source: Gritstone Oncology, Inc